Insider buying last 90 days
No open-market insider purchases were filed for BNTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
BioNTech closed at $87.51 on 9 November 2026, 0% on the day. The price sits below both the 50-day ($94.37) and 200-day ($96.36) moving averages, inside a 52-week range of $79.52 to $124.00. The GekkoIndex reads 61.1, in the Accumulation zone, down 3 points over five sessions. Gekko Fair Value is $84.13, so the price is 4% above it.
The next earnings report is due on 9 March 2027, 114 days away (before open). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 4.1% across the report. Over the last 30 days there was 1 unusual options signal. Seasonally, the next 20 trading days from this point averaged +6% over the last 5 years, rising in 3 of them.
16 firms rate the stock: 12 buy, 4 hold and 0 sell, with a consensus target of $116.30. A typical daily move is about 3.2%, and a typical 20-day move about 7.4%. On the swing-trade checklist, 4 items read supportive and 1 reads as a headwind (trend).
A plain summary of the figures as of the Nov 9, 2026 close.
BioNTech scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
Below 50 and 200-day
Close $85.60 is below the 50-day ($93.08) and 200-day ($95.74) averages, and the 50-day is below the 200-day.
See the chart64.1, Accumulation
Reading 64.1 is in the Accumulation zone.
See the GekkoIndex3.6% above
Price is within 5% of Gekko Fair Value (3.6% above).
See fair valueLeans bullish
Last 30 days: 2 unusual options signals.
See smart moneyReports in 114 days
Next report Mar 9, 2027, 114 days away — outside a typical 20-trading-day hold.
See earnings+3.5% on average
From this point in the calendar, the next 20 trading days averaged +3.5% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
BioNTech closed at $85.60 on Nov 13, 2026, −23.4% over the past year, inside a 52-week range of $79.52 to $124.00.
Use the left and right arrow keys to read daily values.
Put BNTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
BioNTech develops immune-based treatments aimed at cancer and infectious disease. It is widely recognized for its work on cancer vaccines and personalized immunotherapies designed to help the body's own immune system target tumors, alongside preventative vaccines addressing illnesses such as COVID-19 and influenza. Its research also extends to protein replacement approaches for rare conditions.
The company's pipeline spans several distinct treatment classes, including cancer vaccine candidates, neoantigen-targeted therapies, mRNA-based immunotherapies delivered directly into tumors, engineered immune cell treatments, checkpoint modulators, antibody-based candidates and small molecule compounds, most still moving through early to mid-stage clinical trials. To carry this work forward, BioNTech works alongside other pharmaceutical and biotechnology organizations, among them Genentech, Sanofi, Genmab, Pfizer, Shanghai Fosun Pharmaceutical and Regeneron.
BioNTech was founded in 2008 and is headquartered in Mainz, Germany. Its shares trade under the ticker BNTX.
BioNTech’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.1, in the Accumulation zone, up 2 points over five sessions.
Up 2 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 20 | +3.6% | +6.0% | ||
| Accumulation (current zone) | 236 | +0.3% | +3.7% | ||
| Neutral | 370 | 0.0% | −1.1% | ||
| Distribution | 25 | +0.1% | −4.9% | ||
| Selling | 4 | Too few readings yet | |||
Average BNTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
BioNTech trades 3.6% above Gekko Fair Value of $82.63, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what BioNTech shares are worth, recalculated every trading day.
$82.63
Gekko Fair Value, Nov 12, 2026
3.6% above fair value · About fair value
At the end of Aug 2026 the price was 17.3% above the estimate.
No open-market insider purchases were filed for BioNTech, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for BNTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in BNTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
2signals, 100% of the flagged premium in calls.
Latest: Bullish flow on Nov 13, $519K in unusual premium.
0of the funds Gekko tracks hold BNTX.
BioNTech reports on Mar 9, 2027, before the open (114 days away), and beat the EPS estimate in 5 of its last 8 reports.
Mar 9, 2027
Expected before the open, 114 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 3, 2026 | $0.83 est $0.76 | $1.46B est $1.17B | +3.6% |
| Aug 4, 2026 | −$3.03 est −$2.58 | $120.6M est $180.2M | −0.1% |
| Mar 10, 2026 | −$1.44 est −$0.22 | $1.07B est $902.3M | −11.1% |
| Nov 3, 2025 | −$0.14 est −$1.12 | $1.78B est $843.7M | +0.9% |
| Aug 4, 2025 | −$1.82 est −$2.69 | $307.1M est $177.8M | +3.5% |
| Mar 10, 2025 | $1.15 est $0.46 | $1.23B est $1.18B | −9.6% |
| Nov 4, 2024 | $0.88 est −$1.70 | $1.39B est $572.4M | −0.5% |
| Aug 5, 2024 | −$3.36 est −$2.02 | $138.4M est $145.4M | −3.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for BioNTech is $113.50, +32.6% from the last close, from 16 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 16 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 11 | Citi | $125 | +46.0% |
| Nov 10 | H.C. Wainwright | $110 | +28.5% |
| Nov 9 | Morgan Stanley | $106 | +23.8% |
| Nov 9 | H.C. Wainwright | $110 | +28.5% |
| Nov 6 | Bernstein | $96 | +12.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, BioNTech averaged +3.5% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.6% | 1 of 5 |
| Next 10 trading days | +8.8% | 3 of 5 |
| Next 15 trading days | +4.7% | 4 of 5 |
| Next 20 trading days | +3.5% | 3 of 5 |
| Next 30 trading days | −1.9% | 2 of 5 |
For scale, BNTX’s typical 20-trading-day move in either direction is about 7.4%.
BioNTech’s market cap is $21.22B and revenue of $2.42B over the last twelve months.
Coverage of BioNTech this week reads positive: 3 positive, 3 neutral and 0 negative headlines.
BioNTech’s market cap is $21.22B at the Nov 13, 2026 close of $85.60, with 247.9M shares outstanding.
The consensus analyst 12-month price target for BioNTech is $113.50, +32.6% from the last close. Of the 16 firms that rated the stock in the last 90 days, 12 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate BioNTech is about fair value: the Nov 13, 2026 close of $85.60 is 3.6% above Gekko Fair Value of $82.63. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
BioNTech is expected to report on Mar 9, 2027, before the market opens (114 days away). Analysts expect earnings of −$1.89 per share on revenue of $426.3M. BioNTech beat the earnings estimate in 5 of its last 8 reports, moving 4.1% on average across the report.
BioNTech’s 52-week high is $124.00 and its 52-week low is $79.52; it closed at $85.60 on Nov 13, 2026, −23.4% over the past year. Over the last five years the shares peaked at $374.58 on Nov 29, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, smart money, earnings risk and seasonality), 1 as mixed (fair value) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
Gekko flagged 2 unusual options signals in BioNTech over the last 30 days, with $1.11M of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 13, 2026 with $519K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.